CL2013000338A1 - Proteina de union que tiene la capacidad de unirse a interleuquina 1beta y a la interleuquina 17; conjugado de proteina de union cristalizada; acido nucleico, vector, célula huesped; metodo para producir una proteina de unión; composicion farmacéutica que comprende la proteina de unión. - Google Patents

Proteina de union que tiene la capacidad de unirse a interleuquina 1beta y a la interleuquina 17; conjugado de proteina de union cristalizada; acido nucleico, vector, célula huesped; metodo para producir una proteina de unión; composicion farmacéutica que comprende la proteina de unión.

Info

Publication number: CL2013000338A1
Authority: CL; Chile
Prior art keywords: binding protein; interleukin; vector; ability; nucleic acid
Prior art date: 2010-08-03

Application number

CL2013000338A

Other languages

English (en)

Inventor

Peter C Isakson

Tariq Ghayur

Junjian Liu

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-03

Filing date

2013-02-01

Publication date

2013-11-08

2013-02-01 Application filed by Abbvie Inc filed Critical Abbvie Inc

2013-11-08 Publication of CL2013000338A1 publication Critical patent/CL2013000338A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Virology (AREA)
Epidemiology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Oncology (AREA)
Pulmonology (AREA)

CL2013000338A 2010-08-03 2013-02-01 Proteina de union que tiene la capacidad de unirse a interleuquina 1beta y a la interleuquina 17; conjugado de proteina de union cristalizada; acido nucleico, vector, célula huesped; metodo para producir una proteina de unión; composicion farmacéutica que comprende la proteina de unión. CL2013000338A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37026910P	2010-08-03	2010-08-03
US37713410P	2010-08-26	2010-08-26

Publications (1)

Publication Number	Publication Date
CL2013000338A1 true CL2013000338A1 (es)	2013-11-08

Family

ID=45556314

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000338A CL2013000338A1 (es)	2010-08-03	2013-02-01	Proteina de union que tiene la capacidad de unirse a interleuquina 1beta y a la interleuquina 17; conjugado de proteina de union cristalizada; acido nucleico, vector, célula huesped; metodo para producir una proteina de unión; composicion farmacéutica que comprende la proteina de unión.

Country Status (24)

Country	Link
US (5)	US8735546B2 (es)
EP (2)	EP2601218A4 (es)
JP (2)	JP2013537415A (es)
KR (1)	KR20130100118A (es)
CN (1)	CN103298834A (es)
AR (1)	AR082461A1 (es)
AU (1)	AU2011285852B2 (es)
BR (1)	BR112013002578A2 (es)
CA (1)	CA2807014A1 (es)
CL (1)	CL2013000338A1 (es)
CO (1)	CO6680687A2 (es)
CR (1)	CR20130058A (es)
DO (1)	DOP2013000025A (es)
EC (1)	ECSP13012462A (es)
MX (1)	MX341579B (es)
MY (1)	MY160445A (es)
NZ (1)	NZ607480A (es)
PE (1)	PE20131412A1 (es)
PH (1)	PH12013500207A1 (es)
RU (1)	RU2013109275A (es)
SG (1)	SG188190A1 (es)
TW (1)	TW201206473A (es)
UY (1)	UY33543A (es)
WO (1)	WO2012018790A2 (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2899209A1 (en) *	2008-04-29	2015-07-29	Abbvie Inc.	Dual Variable Domain Immunoglobulins and uses thereof
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0913406A2 (pt)	2008-06-03	2018-01-09	Abbott Lab	imunoglobulinas de domínio variável duplo e usos das mesmas
EP2297208A4 (en) *	2008-06-03	2012-07-11	Abbott Lab	DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US8822645B2 (en) *	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
TW201613969A (en)	2009-03-05	2016-04-16	Abbvie Inc	IL-17 binding proteins
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CA2771575A1 (en)	2009-08-29	2011-03-03	Abbott Laboratories	Therapeutic dll4 binding proteins
RU2012112550A (ru) *	2009-09-01	2013-10-10	Эбботт Лэборетриз	Иммуноглобулины с двумя вариабельными доменами и их применение
US8716450B2 (en) *	2009-10-15	2014-05-06	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2791631A1 (en)	2010-03-02	2011-09-09	Abbvie Inc.	Therapeutic dll4 binding proteins
KR20130010123A (ko)	2010-04-07	2013-01-25	아비에 인코포레이티드	ＴＮＦ-α 결합 단백질
US8841417B2 (en) *	2010-05-14	2014-09-23	Abbvie Inc.	IL-1 binding proteins
TW201206473A (en)	2010-08-03	2012-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
US8956859B1 (en)	2010-08-13	2015-02-17	Aviex Technologies Llc	Compositions and methods for determining successful immunization by one or more vaccines
PE20140229A1 (es)	2010-08-26	2014-03-27	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130133247A (ko) *	2010-12-21	2013-12-06	애브비 인코포레이티드	Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
CN104203978A (zh)	2011-10-24	2014-12-10	艾伯维股份有限公司	针对硬化蛋白的免疫结合剂
IN2014CN03936A (es)	2011-10-24	2015-09-04	Abbvie Inc
HK1200321A1 (en)	2011-10-24	2015-08-07	Abbvie Inc.	Bispecific immunobinders directed against tnf and il-17
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CN104245738B (zh)	2012-04-05	2018-02-02	弗·哈夫曼-拉罗切有限公司	针对人tweak和人il17的双特异性抗体及其用途
HK1207654A1 (en) *	2012-04-27	2016-02-05	Bioatla, Llc	Modified antibody regions and uses thereof
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
WO2014037811A2 (en)	2012-09-07	2014-03-13	The Governors Of The University Of Alberta	Methods and compositions for diagnosis of inflammatory liver disease
UY35110A (es)	2012-11-01	2014-05-30	Abbvie Inc	Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
EP2919811B1 (en)	2012-11-16	2018-12-26	Novartis AG	Use of il-1beta binding antibodies for treating peripheral arterial disease
TW201446800A (zh) *	2013-03-15	2014-12-16	Abbvie Inc	針對ＴＮＦα之雙特異性結合蛋白
CA2904448A1 (en) *	2013-03-15	2014-09-18	Tariq Ghayur	Dual specific binding proteins directed against il-1.beta. and/or il-17
WO2015014979A1 (en)	2013-08-01	2015-02-05	F. Hoffmann-La Roche Ag	Tnfa-il-17 bispecific antibodies
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3049442A4 (en)	2013-09-26	2017-06-28	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2936962C (en)	2014-03-14	2024-03-05	Novartis Ag	Antibody molecules to lag-3 and uses thereof
US20160002326A1 (en) *	2014-06-10	2016-01-07	Abbvie Inc.	Compositions and methods for treating rheumatoid arthritis
CA2955984A1 (en)	2014-07-22	2016-01-28	The University Of Notre Dame Du Lac	Molecular constructs and uses thereof
AU2015314240A1 (en) *	2014-09-10	2017-02-09	AbbVie Deutschland GmbH & Co. KG	RGMa fragment based diagnostic assay
CA2960824A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of alk inhibitors
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
WO2016103093A1 (en) *	2014-12-23	2016-06-30	Pfizer Inc.	Stable aqueous antibody formulation for anti tnf alpha antibodies
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
UA123053C2 (uk)	2015-06-24	2021-02-10	Ф. Хоффманн-Ля Рош Аг	Антитіло до рецептора трансферину зі спеціально підібраною афінністю
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP6990650B2 (ja) *	2015-09-17	2022-03-04	ザスクリプスリサーチインスティテュート	二重可変ドメインイムノコンジュゲートおよびその用途
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43023A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
JP2018536152A (ja) *	2015-10-08	2018-12-06	ザヘンリーエム．ジャクソンファウンデーションフォーザアドヴァンスメントオブミリタリーメディシンインコーポレイテッド	心的外傷後ストレス障害を診断するためのバイオマーカー
PE20181953A1 (es)	2016-03-02	2018-12-17	Eisai Randd Man Co Ltd	Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
KR102460040B1 (ko)	2016-04-27	2022-11-01	애브비 인코포레이티드	항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
GB201610198D0 (en)	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JOP20180027A1 (ar)	2017-03-28	2019-01-30	Cell Design Labs Inc	بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
CN107167590B (zh) *	2017-04-14	2019-03-08	江苏福隆生物技术有限公司	糖类抗原242的板式化学发光法检测试剂盒及制备方法
CN107085111B (zh) *	2017-04-14	2019-02-01	江苏福隆生物技术有限公司	乙型肝炎病毒前s1抗原的板式化学发光法检测试剂盒及制备方法
US11325957B2 (en)	2017-06-19	2022-05-10	Cell Design Labs, Inc.	Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN107490695B (zh) *	2017-07-10	2019-10-25	江苏福隆生物技术有限公司	糖类抗原50的板式化学发光法检测试剂盒及制备方法
CN107462721B (zh) *	2017-07-10	2019-10-25	江苏福隆生物技术有限公司	细胞角蛋白19片段的板式化学发光法检测试剂盒及制备方法
MY207644A (en)	2017-12-19	2025-03-07	Akouos Inc	Aav-mediated delivery of therapeutic antibodies to the inner ear
US20190194617A1 (en)	2017-12-22	2019-06-27	Cell Design Labs, Inc.	Single- and multi-chain chimeric antigen receptors
US20200384030A1 (en)	2018-02-21	2020-12-10	Cell Design Labs, Inc.	Chimeric transmembrane receptors and uses thereof
US20200041518A1 (en)	2018-08-03	2020-02-06	CellMax Life, Inc.	Lipid vesicle-coated magnetic beads and uses of the same
JP7474769B2 (ja)	2018-08-30	2024-04-25	エイチシーダブリューバイオロジックスインコーポレイテッド	一本鎖および多鎖キメラポリペプチドならびにその使用方法
CN113365663B (zh)	2018-08-30	2025-11-21	免疫生物公司	单链嵌合多肽和其用途
KR20250160211A (ko)	2018-08-30	2025-11-11	이뮤니티바이오, 인크.	다중-사슬 키메라 폴리펩타이드 및 이의 용도
AU2020262231A1 (en)	2019-04-23	2021-12-16	Sanofi	Stable, low-viscosity antibody formulations and uses thereof
EP3980127A1 (en)	2019-06-06	2022-04-13	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
US20220324969A1 (en)	2019-06-06	2022-10-13	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
WO2020247873A1 (en)	2019-06-07	2020-12-10	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
US11738052B2 (en)	2019-06-21	2023-08-29	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
US20220306751A1 (en)	2019-09-13	2022-09-29	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
WO2021067673A1 (en)	2019-10-04	2021-04-08	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
WO2021141996A1 (en)	2020-01-06	2021-07-15	Cytomx Therapeutics, Inc.	Single- and multi-chain polypeptides that bind specifically to cd3 epsilon
KR20220140535A (ko)	2020-02-11	2022-10-18	에이치씨더블유 바이올로직스, 인크.	크로마토그래피 수지 및 이의 용도
CA3169231A1 (en)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methods of treating age-related and inflammatory diseases
WO2021163298A1 (en)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methods of activating regulatory t cells
CN111560383A (zh) *	2020-03-14	2020-08-21	天津大学青岛海洋技术研究院	促进枯草芽孢杆菌合成甲萘醌-7的重组菌及其基因修饰方法
IL296723A (en)	2020-03-26	2022-11-01	Seagen Inc	Methods of treating multiple myeloma
JP7734693B2 (ja)	2020-04-29	2025-09-05	イミュニティーバイオインコーポレイテッド	抗ｃｄ２６タンパク質及びそれらの使用法
CA3184756A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
WO2021247003A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
WO2022119839A1 (en)	2020-12-01	2022-06-09	Akouos, Inc.	Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
EP4494660A3 (en)	2021-02-03	2025-04-16	Mythic Therapeutics, Inc.	Anti-met antibodies and uses thereof
WO2022198231A1 (en)	2021-03-18	2022-09-22	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
MX2023011919A (es)	2021-04-07	2023-10-19	Mythic Therapeutics Inc	Construcciones de proteinas de union a antigenos y anticuerpos y usos de estos.
JP2024532760A (ja)	2021-08-11	2024-09-10	エイチシーダブリューバイオロジックスインコーポレイテッド	多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
TW202327650A (zh)	2021-09-23	2023-07-16	美商思進公司	治療多發性骨髓瘤之方法
AU2023215253A1 (en)	2022-02-02	2024-09-19	Akouos, Inc.	Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
WO2023159110A1 (en) *	2022-02-16	2023-08-24	The General Hospital Corporation	Contact-type patches for staining
AU2023228683B2 (en)	2022-03-02	2025-12-04	Immunitybio, Inc.	Method of treating pancreatic cancer
US20250230239A1 (en)	2022-04-01	2025-07-17	Cytomx Therapeutics, Inc.	Cd3-binding proteins and methods of use thereof
JP2025513831A (ja)	2022-04-13	2025-04-30	イミュニティバイオ，インコーポレーテッド	神経炎症性障害の処置における使用のための多重鎖キメラポリペプチド
KR20250004747A (ko)	2022-04-13	2025-01-08	이뮤니티바이오, 인크.	생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
KR20250012620A (ko)	2022-05-19	2025-01-24	마이틱 테라퓨틱스, 인크.	Ph 의존적으로 결합하는 ptk7-결합 단백질 및 이의 용도
WO2024030858A1 (en)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Protease-cleavable substrates and methods of use thereof
AR130077A1 (es)	2022-08-01	2024-10-30	Cytomx Therapeutics Inc	Substratos escindibles por proteasas, y métodos de uso de los mismos
EP4565690A1 (en)	2022-08-01	2025-06-11	CytomX Therapeutics, Inc.	Protease-cleavable moieties and methods of use thereof
TW202424184A (zh)	2022-08-01	2024-06-16	美商Ｃｙｔｏｍｘ生物製藥公司	蛋白酶可切割部分及其使用方法
WO2024030845A1 (en)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Protease-cleavable moieties and methods of use thereof
EP4602072A2 (en)	2022-10-12	2025-08-20	Mythic Therapeutics, Inc.	Lrrc-15-binding protein constructs and uses thereof
CN121152811A (zh)	2023-03-29	2025-12-16	神话治疗股份有限公司	Trop2结合蛋白以及其用途
WO2024263932A2 (en)	2023-06-23	2024-12-26	Mythic Therapeutics, Inc.	Itgb6-binding proteins and uses thereof
US20250295801A1 (en)	2024-03-21	2025-09-25	Seagen Inc.	Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025212647A1 (en)	2024-04-01	2025-10-09	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof

Family Cites Families (439)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2040108A (en)	1935-04-11	1936-05-12	Air Reduction	Recovery of krypton and xenon
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
EP0092918B1 (en)	1982-04-22	1988-10-19	Imperial Chemical Industries Plc	Continuous release formulations
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
FR2556739A1 (fr)	1983-12-19	1985-06-21	Pasteur Institut	Lignees cellulaires secretant des anticorps monoclonaux contre la pg e2, leur preparation, les anticorps obtenus et leur application
US4753894A (en)	1984-02-08	1988-06-28	Cetus Corporation	Monoclonal anti-human breast cancer antibodies
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5128326A (en)	1984-12-06	1992-07-07	Biomatrix, Inc.	Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
DE3546806C2 (es)	1985-03-30	1991-03-28	Marc Genf/Geneve Ch Ballivet
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3683541D1 (de)	1985-06-07	1992-03-05	Ici America Inc	Selektionierte difluorverbindungen.
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de)	1986-01-15	1987-07-16	Ant Nachrichtentech	Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US4699784A (en)	1986-02-25	1987-10-13	Center For Molecular Medicine & Immunology	Tumoricidal methotrexate-antibody conjugate
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
EP0273115B1 (en)	1986-10-22	1994-09-07	Abbott Laboratories	Chemiluminescent acridinium and phenanthridinium salts
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US4880078A (en)	1987-06-29	1989-11-14	Honda Giken Kogyo Kabushiki Kaisha	Exhaust muffler
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5006309A (en)	1988-04-22	1991-04-09	Abbott Laboratories	Immunoassay device with liquid transfer between wells by washing
US5089424A (en)	1988-06-14	1992-02-18	Abbott Laboratories	Method and apparatus for heterogeneous chemiluminescence assay
EP0436597B1 (en)	1988-09-02	1997-04-02	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5241070A (en)	1988-09-26	1993-08-31	Ciba Corning Diagnostics Corp.	Nucleophilic polysubstituted aryl acridinium esters and uses thereof
AU643427B2 (en)	1988-10-31	1993-11-18	Immunex Corporation	Interleukin-4 receptors
SE462454B (sv)	1988-11-10	1990-06-25	Pharmacia Ab	Maetyta foer anvaendning i biosensorer
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5063081A (en)	1988-11-14	1991-11-05	I-Stat Corporation	Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
CA2016842A1 (en)	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
CA2016841C (en)	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
CA2057923A1 (en)	1989-05-16	1990-11-17	William D. Huse	Co-expression of heteromeric receptors
AU6430190A (en)	1989-10-10	1991-05-16	Pitman-Moore, Inc.	Sustained release composition for macromolecular proteins
EP0550436A1 (en)	1989-11-06	1993-07-14	Alkermes Controlled Therapeutics, Inc.	Protein microspheres and methods of using them
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AT396939B (de)	1990-05-29	1993-12-27	Alois Dipl Ing Dr Jungbauer	Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
ES2139598T3 (es)	1990-07-10	2000-02-16	Medical Res Council	Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
US5135875A (en)	1990-08-15	1992-08-04	Abbott Laboratories	Protein precipitation reagent
AU8505191A (en)	1990-08-24	1992-03-17	Ixsys, Inc.	Methods of synthesizing oligonucleotides with random codons
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
WO1992009690A2 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with altered binding properties
US5780279A (en)	1990-12-03	1998-07-14	Genentech, Inc.	Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
WO1992011272A1 (en)	1990-12-20	1992-07-09	Ixsys, Inc.	Optimization of binding proteins
ATE439435T1 (de)	1991-03-01	2009-08-15	Dyax Corp	Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
CZ282603B6 (cs)	1991-03-06	1997-08-13	Merck Patent Gesellschaft Mit Beschränkter Haftun G	Humanizované a chimerické monoklonální protilátky
DE69233701T2 (de)	1991-03-18	2008-04-10	New York University	Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en)	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP1471142B1 (en)	1991-04-10	2008-11-19	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
US5795965A (en)	1991-04-25	1998-08-18	Chugai Seiyaku Kabushiki Kaisha	Reshaped human to human interleukin-6 receptor
ATE221379T1 (de)	1991-05-01	2002-08-15	Jackson H M Found Military Med	Verfahren zur behandlung infektiöser respiratorischer erkrankungen
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
CA2069530A1 (en)	1991-06-03	1992-12-04	Cass J. Grandone	Reagent pack for immunoassays
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
CA2110799A1 (en)	1991-06-14	1992-12-23	Arnold H. Horwitz	Microbially-produced antibody fragments and their conjugates
CA2103059C (en)	1991-06-14	2005-03-22	Paul J. Carter	Method for making humanized antibodies
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
EP1136556B1 (en)	1991-11-25	2005-06-08	Enzon, Inc.	Method of producing multivalent antigen-binding proteins
WO1993011236A1 (en)	1991-12-02	1993-06-10	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993011794A1 (en)	1991-12-13	1993-06-24	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en)	1992-03-12	1999-06-15	Alkermes Controlled Therapeutics, Inc.	Modulated release from biocompatible polymers
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5352803A (en)	1992-03-30	1994-10-04	Abbott Laboratories	5(6)-methyl substituted fluorescein derivatives
ES2148225T3 (es)	1992-03-30	2000-10-16	Abbott Lab	Reactivos y procedimientos que permiten la deteccion y la cuantificacion de la tiroxina en muestras de fluido.
SG48760A1 (en)	1992-07-24	2003-03-18	Abgenix Inc	Generation of xenogenetic antibodies
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
PT752248E (pt)	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5934272A (en)	1993-01-29	1999-08-10	Aradigm Corporation	Device and method of creating aerosolized mist of respiratory drug
AU6132994A (en)	1993-02-02	1994-08-29	Scripps Research Institute, The	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6491916B1 (en)	1994-06-01	2002-12-10	Tolerance Therapeutics, Inc.	Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO1995001997A1 (en) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1995009917A1 (en)	1993-10-07	1995-04-13	The Regents Of The University Of California	Genetically engineered bispecific tetravalent antibodies
EP0659766A1 (en)	1993-11-23	1995-06-28	Schering-Plough	Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5565352A (en)	1993-11-24	1996-10-15	Arch Development Corporation	Deubiquitinating enzyme: compositions and methods
AU696293B2 (en)	1993-12-08	1998-09-03	Genzyme Corporation	Process for generating specific antibodies
CA2178590A1 (en)	1993-12-10	1995-06-15	Joan D. Tyner	Reagents and methods for the detection of methotrexate
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
DK0744958T3 (da)	1994-01-31	2003-10-20	Univ Boston	Polyklonale antistofbiblioteker
ZA95960B (en)	1994-03-14	1995-10-10	Genetics Inst	Use of interleukin-12 antagonists in the treatment of autoimmune diseases
PL181342B1 (pl)	1994-03-17	2001-07-31	Merck Patent Gmbh	Jednolancuchowe anty-EGFR Fv i przeciwciala anty-EGFR, czasteczka DNA, sposoby wytwarzania jednolancuchowego przeciwciala anty-EGFR i przeciwciala anty-EGFR oraz kompozycja farmaceutyczna PL PL PL PL PL PL PL
IL109632A (en)	1994-05-11	2007-03-08	Yeda Res & Dev	Modulators of the function of tnf receptors
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE69534530T2 (de)	1994-08-12	2006-07-06	Immunomedics, Inc.	Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
DE69630514D1 (de)	1995-01-05	2003-12-04	Univ Michigan	Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9504344D0 (en)	1995-03-03	1995-04-19	Unilever Plc	Antibody fragment production
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en)	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
AU705616B2 (en)	1995-04-21	1999-05-27	Cell Genesys, Inc.	Generation of large genomic DNA deletions
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
WO1996040210A1 (en)	1995-06-07	1996-12-19	Imclone Systems Incorporated	Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en)	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
WO1997007788A2 (en)	1995-08-31	1997-03-06	Alkermes Controlled Therapeutics, Inc.	Composition for sustained release of an agent
WO1997014719A1 (en)	1995-10-16	1997-04-24	Unilever N.V.	A bifunctional or bivalent antibody fragment analogue
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US6331431B1 (en)	1995-11-28	2001-12-18	Ixsys, Inc.	Vacuum device and method for isolating periplasmic fraction from cells
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
BRPI9707379C8 (pt)	1996-02-09	2017-12-12	Abbott Biotech Ltd	composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
DK0885002T3 (da)	1996-03-04	2011-08-22	Penn State Res Found	Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
NZ331688A (en)	1996-03-28	2000-02-28	Univ Johns Hopkins	Soluble divalent and multivalent heterodimeric analogs of proteins
JP2000508892A (ja)	1996-04-04	2000-07-18	ユニリーバー・ナームローゼ・ベンノートシャープ	多価および多特異的抗原結合タンパク
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US6699658B1 (en)	1996-05-31	2004-03-02	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US6986890B1 (en)	1996-11-21	2006-01-17	Kyowa Hakko Kogyo Co., Ltd.	Anti-human VEGF receptor Flt-1 monoclonal antibody
US7258857B2 (en)	1996-11-22	2007-08-21	The Trustees Of Columbia University In The City Of New York	Rage-related methods for treating inflammation
ES2301183T3 (es)	1996-12-03	2008-06-16	Amgen Fremont Inc.	Anticuerpo completamente humano que se une al receptor del egfr.
ATE287257T1 (de)	1997-01-16	2005-02-15	Massachusetts Inst Technology	Zubereitung von partikelhaltigen arzneimitteln zur inhalation
DE69835143T2 (de)	1997-01-21	2007-06-06	The General Hospital Corp., Boston	Selektion von proteinen mittels rns-protein fusionen
US7306914B2 (en)	1997-01-31	2007-12-11	Odyssey Thera Inc.	Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy
US6057098A (en)	1997-04-04	2000-05-02	Biosite Diagnostics, Inc.	Polyvalent display libraries
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
ES2273415T3 (es)	1997-04-07	2007-05-01	Genentech, Inc.	Anticuerpos anti-vegf.
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
NZ516848A (en)	1997-06-20	2004-03-26	Ciphergen Biosystems Inc	Retentate chromatography apparatus with applications in biology and medicine
WO1999006834A2 (en)	1997-08-04	1999-02-11	Ixsys, Incorporated	Methods for identifying ligand specific binding molecules
US5989463A (en)	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv)	1997-10-23	2000-04-17	Biogram Ab	Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP1027439B1 (en)	1997-10-27	2010-03-17	Bac Ip B.V.	Multivalent antigen-binding proteins
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
WO1999045031A2 (en)	1998-03-03	1999-09-10	Abgenix, Inc.	Cd147 binding molecules as therapeutics
WO1999051773A1 (en)	1998-04-03	1999-10-14	Phylos, Inc.	Addressable protein arrays
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
PT1071700E (pt)	1998-04-20	2010-04-23	Glycart Biotechnology Ag	Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR100960211B1 (ko)	1998-05-06	2010-05-27	제넨테크, 인크.	이온 교환 크로마토그래피에 의한 단백질 정제 방법
AU747231B2 (en)	1998-06-24	2002-05-09	Alkermes, Inc.	Large porous particles emitted from an inhaler
US6406921B1 (en)	1998-07-14	2002-06-18	Zyomyx, Incorporated	Protein arrays for high-throughput screening
AU770555B2 (en)	1998-08-17	2004-02-26	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
US20030215458A1 (en)	1998-09-30	2003-11-20	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
WO2000034337A1 (en)	1998-12-10	2000-06-15	Tsukuba Research Laboratory, Toagosei Co., Ltd.	Humanized monoclonal antibodies against vascular endothelial cell growth factor
SG143018A1 (en)	1998-12-23	2008-06-27	Pfizer	Human monoclonal antibodies to ctla-4
US8003772B2 (en)	1999-01-14	2011-08-23	Martek Biosciences Corporation	Chimeric PUFA polyketide synthase systems and uses thereof
ES2694002T3 (es)	1999-01-15	2018-12-17	Genentech, Inc.	Polipéptido que comprende una región Fc de IgG1 humana variante
AU4025300A (en)	1999-03-24	2000-10-09	Packard Bioscience Company	Continuous porous matrix arrays
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
EP2319870A3 (en)	1999-03-25	2011-10-26	Abbott GmbH & Co. KG	Human antibodies that bind human IL-12 and methods for producing
WO2000061739A1 (fr)	1999-04-09	2000-10-19	Kyowa Hakko Kogyo Co., Ltd.	Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
CN1119415C (zh)	1999-06-04	2003-08-27	长春迈灵生物工程有限公司	抗ca125双功能基因工程抗体的克隆与表达
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
US6531580B1 (en)	1999-06-24	2003-03-11	Ixsys, Inc.	Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
KR20020012292A (ko)	1999-06-25	2002-02-15	제넨테크, 인크.	항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
EP1230269A2 (en)	1999-11-03	2002-08-14	Maxygen, Inc.	Antibody diversity generation
BR0108188A (pt)	2000-02-10	2003-02-25	Abbott Lab	Anticorpos que se ligam a interleucina-18 humana e métodos de produção e uso
PL358187A1 (en)	2000-02-24	2004-08-09	Genentech, Inc.	Caspase activated prodrugs therapy
EP1266009B1 (en)	2000-02-25	2008-12-31	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
US7094566B2 (en)	2000-03-16	2006-08-22	Amgen Inc.,	IL-17 receptor like molecules and uses thereof
US20040038339A1 (en)	2000-03-24	2004-02-26	Peter Kufer	Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
PT2857516T (pt)	2000-04-11	2017-08-28	Genentech Inc	Anticorpos multivalentes e utilizações dos mesmos
MXPA02010787A (es)	2000-05-03	2003-07-14	Amgen Inc	Peptidos modificados como agentes terapeuticos.
ES2259030T3 (es)	2000-05-19	2006-09-16	Scancell Limited	Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ATE309385T1 (de)	2000-06-28	2005-11-15	Glycofi Inc	Verfahren für die herstellung modifizierter glykoproteine
MXPA02012867A (es)	2000-06-29	2003-09-05	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
CA2410551A1 (en)	2000-06-30	2002-01-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib)	Heterodimeric fusion proteins
US20090081234A1 (en)	2000-08-07	2009-03-26	George Heavner	Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
US20030157643A1 (en)	2000-08-24	2003-08-21	Almond Brian D	Synthetic nucleic acids from aquatic species
AU2002211658A1 (en)	2000-10-13	2002-04-22	Uab Research Foundation	Human anti-epidermal growth factor receptor single-chain antibodies
JP5312721B2 (ja)	2000-11-07	2013-10-09	シティ・オブ・ホープ	Ｃｄ１９特異的再指向免疫細胞
US7601692B2 (en)	2000-11-28	2009-10-13	Compugen Ltd.	MCP-1 splice variants and methods of using same
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6818392B2 (en)	2000-12-06	2004-11-16	Abbott Laboratories	Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP2325205A3 (en)	2000-12-28	2011-10-12	Altus Pharmaceuticals Inc.	Crystals of whole antibodies and fragments thereof and methods for making and using them
MA26040A1 (fr)	2001-01-05	2004-04-01	Pfizer	Des anticorps pour recepteur i de facteur de croissance insulinique
US7667004B2 (en)	2001-04-17	2010-02-23	Abmaxis, Inc.	Humanized antibodies against vascular endothelial growth factor
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
WO2002096458A1 (en)	2001-05-30	2002-12-05	Genentech, Inc.	Anti-ngf antibodies for the treatment of various disorders
WO2002097048A2 (en)	2001-05-30	2002-12-05	Centocor, Inc.	ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
RU2335507C2 (ru)	2001-06-13	2008-10-10	Генмаб А/С	Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
JP4249013B2 (ja)	2001-07-31	2009-04-02	佑本庶	Ｐｄ−１に対し特異性を有する物質
EP1432444A4 (en)	2001-08-17	2005-11-02	Lilly Co Eli	ANTI-BETA ANTIBODIES
US7247304B2 (en)	2001-08-23	2007-07-24	Genmab A/S	Methods of treating using anti-IL-15 antibodies
US20030226155A1 (en)	2001-08-30	2003-12-04	Biorexis Pharmaceutical Corporation	Modified transferrin-antibody fusion proteins
AU2002332290B2 (en)	2001-09-25	2007-11-08	Astellas Pharma Inc.	Recombinant anti-osteopontin antibody and use thereof
CA2462113C (en)	2001-10-01	2013-01-29	Dyax Corp.	Multi-chain eukaryotic display vectors and uses thereof
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
NZ532526A (en)	2001-10-25	2007-01-26	Genentech Inc	Compositions comprising a glycoprotein having a Fc region
WO2003039486A2 (en)	2001-11-09	2003-05-15	Idec Pharmaceuticals Corporation	Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
DE10156482A1 (de)	2001-11-12	2003-05-28	Gundram Jung	Bispezifisches Antikörper-Molekül
CN100374457C (zh)	2001-11-14	2008-03-12	森托科尔公司	抗il-6抗体、组合物、方法和用途
WO2003062375A2 (en)	2001-12-19	2003-07-31	Genentech, Inc.	Stabilizing polypeptides which have been exposed to urea
AU2003210802B2 (en)	2002-02-05	2009-09-10	Genentech Inc.	Protein purification
BR0307548A (pt)	2002-02-11	2006-01-17	Genentech Inc	Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
US7657380B2 (en)	2003-12-04	2010-02-02	Xencor, Inc.	Methods of generating variant antibodies with increased host string content
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US7419821B2 (en)	2002-03-05	2008-09-02	I-Stat Corporation	Apparatus and methods for analyte measurement and immunoassay
JP2005535572A (ja)	2002-04-12	2005-11-24	メディミューン，インコーポレーテッド	組換え抗インターロイキン−９抗体
EP1495055B1 (en)	2002-04-18	2013-08-14	Genencor International, Inc.	Production of functional antibodies in filamentous fungi
JP4319979B2 (ja)	2002-04-26	2009-08-26	ジェネンテック・インコーポレーテッド	タンパク質の非アフィニティ精製
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
WO2003093317A1 (en)	2002-04-30	2003-11-13	Kyowa Hakko Kogyo Co., Ltd.	Antibody to human insulin-like growth factor
US7714189B2 (en)	2002-05-03	2010-05-11	Monsanto Technology Llc	High tryptophan maize
EP2316921B1 (en)	2002-05-24	2014-05-14	Merck Sharp & Dohme Corp.	Neutralizing human anti-IGFR antibody
DE60305919T2 (de)	2002-06-28	2007-01-18	Domantis Limited, Cambridge	Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
CN105884893A (zh)	2002-07-18	2016-08-24	莫鲁斯有限公司	抗体混合物的重组生产
US20040018577A1 (en)	2002-07-29	2004-01-29	Emerson Campbell John Lewis	Multiple hybrid immunoassay
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
UA87979C2 (ru)	2002-08-19	2009-09-10	Астразенека Аб	Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
JP5303092B2 (ja)	2002-09-11	2013-10-02	ジェネンテック，インコーポレイテッド	タンパク質精製
US7820166B2 (en)	2002-10-11	2010-10-26	Micromet Ag	Potent T cell modulating molecules
KR20100039428A (ko)	2002-11-22	2010-04-15	에자이 알앤드디 매니지먼트 가부시키가이샤	말라리아 기생충에서 ｇｐｉ의 생합성을 억제하는 화합물을 스크리닝하는 방법
CA2508375C (en)	2002-12-02	2014-05-27	Abgenix, Inc.	Antibodies directed to tumor necrosis factor and uses thereof
AR042485A1 (es)	2002-12-16	2005-06-22	Genentech Inc	Anticuerpo humanizado que se une al cd20 humano
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
CA2511598C (en)	2002-12-24	2016-09-13	Rinat Neuroscience Corp.	Anti-ngf antibodies and methods using same
US7575893B2 (en)	2003-01-23	2009-08-18	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP3803790B2 (ja)	2003-02-17	2006-08-02	株式会社東北テクノアーチ	新規なダイアボディ型二重特異性抗体
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ES2564103T3 (es)	2003-03-05	2016-03-17	Halozyme, Inc.	Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
JP2007535895A (ja)	2003-05-01	2007-12-13	イムクローンシステムズインコーポレイティド	ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
MXPA05012201A (es)	2003-05-14	2006-02-10	Dow Corning	Conjugados de agentes activos de polimero de proteina de secuencia de repeticion, metodos y usos.
US20070104722A1 (en)	2003-05-15	2007-05-10	Iogenetics	Targeted biocides
RU2005141512A (ru)	2003-05-31	2007-07-20	Микромет Аг (De)	Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
AR042955A1 (es)	2003-07-18	2005-07-13	Amgen Inc	Agentes de union especifica al factor de crecimiento de hepatocitos
EP3095793B1 (en)	2003-07-28	2020-03-25	Genentech, Inc.	Reducing protein a leaching during protein a affinity chromatography
US20050026881A1 (en)	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
US7662928B2 (en)	2003-08-08	2010-02-16	The Research Foundation Of State University Of New York	Anti-FcRn antibodies for treatment of auto/allo immune conditions
US20050042664A1 (en)	2003-08-22	2005-02-24	Medimmune, Inc.	Humanization of antibodies
EP2502935B1 (en)	2003-08-22	2017-03-29	Biogen MA Inc.	Improved antibodies having altered effector function and methods for making the same
US7682833B2 (en)	2003-09-10	2010-03-23	Abbott Point Of Care Inc.	Immunoassay device with improved sample closure
US7723099B2 (en)	2003-09-10	2010-05-25	Abbott Point Of Care Inc.	Immunoassay device with immuno-reference electrode
US20060134105A1 (en)	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
CN1997897A (zh)	2003-10-24	2007-07-11	梅德特龙尼克有限公司	通过削弱促炎介质的产生治疗神经病症的技术
US7968684B2 (en)	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
EP2264191A1 (en)	2003-11-21	2010-12-22	ANP Technologies, Inc.	Asymmetrically branched polymer conjugates and microarray assays
CA2548749A1 (en)	2003-12-09	2005-06-23	Ventria Bioscience	High-level expression of fusion polypeptides in plant seeds utilizing seed-storage proteins as fusion carriers
US7235641B2 (en)	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
ITRM20030601A1 (it)	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7297541B2 (en)	2004-01-26	2007-11-20	Monsanto Technology Llc	Genes encoding 4-hydroxyphenylpyruvate dioxygenase (HPPD) enzymes for plant metabolic engineering
US7794713B2 (en)	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2562771C (en)	2004-04-12	2013-04-09	Medimmune, Inc.	Anti-il-9 antibody formulations and uses thereof
JP2007535317A (ja)	2004-04-15	2007-12-06	グライコフィ，インコーポレイテッド	下等真核生物におけるガラクトシル化された糖タンパク質の産生
US7976841B2 (en)	2004-04-30	2011-07-12	Institut National De La Sante Et De La Recherche	Anti TfR antibody
CA2566647A1 (en)	2004-05-13	2005-12-22	Imclone Systems Incorporated	Inhibition of macrophage-stimulating protein receptor (ron)
WO2005112597A2 (en)	2004-05-19	2005-12-01	Agrivida, Inc.	Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production
WO2006001965A2 (en)	2004-05-24	2006-01-05	Abgenix, Inc.	Reducing the risk of human anti-human antibodies through v gene manipulation
WO2005118635A2 (en)	2004-06-03	2005-12-15	Novimmune S.A.	Anti-cd3 antibodies and methods of use thereof
US7150969B2 (en)	2004-06-04	2006-12-19	Rosetta Inpharmatics Llc	Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2)
WO2006020258A2 (en)	2004-07-17	2006-02-23	Imclone Systems Incorporated	Novel tetravalent bispecific antibody
MX2007001221A (es)	2004-08-04	2007-03-23	Amgen Inc	Anticuerpos para proteina dickkopf-1 (dkk-1).
US7476724B2 (en)	2004-08-05	2009-01-13	Genentech, Inc.	Humanized anti-cmet antibodies
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
KR20070057839A (ko)	2004-08-19	2007-06-07	제넨테크, 인크.	변경된 이펙터 기능을 갖는 폴리펩티드 변이체
GB0419424D0 (en)	2004-09-02	2004-10-06	Viragen Scotland Ltd	Transgene optimisation
HRP20120171T1 (hr)	2004-09-03	2012-03-31	Genentech	Humanizirani anti-beta 7 antagonisti i njihove uporabe
WO2006037604A1 (en)	2004-10-01	2006-04-13	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Novel antibodies directed to the mammalian eag1 ion channel protein
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
WO2006047350A2 (en)	2004-10-21	2006-05-04	Xencor, Inc.	IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005299716B2 (en)	2004-10-22	2012-09-06	Amgen Inc.	Methods for refolding of recombinant antibodies
US20060253100A1 (en)	2004-10-22	2006-11-09	Medtronic, Inc.	Systems and Methods to Treat Pain Locally
US7423128B2 (en)	2004-11-03	2008-09-09	Amgen Fremont Inc.	Anti-properdin antibodies, and methods for making and using same
US20070135620A1 (en)	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
EP1819731A4 (en)	2004-12-08	2013-02-13	Immunomedics Inc	METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
PE20061401A1 (es)	2004-12-15	2006-12-23	Neuralab Ltd	ANTICUERPOS Aß PARA MEJORAR LA COGNICION
US20080267971A1 (en)	2004-12-21	2008-10-30	Green Larry L	Antibodies Directed to Angiopoietin-2 and Uses Thereof
WO2006118617A2 (en)	2004-12-23	2006-11-09	Chlorogen, Inc.	EXPRESSING TGF-β PROTEINS IN PLANT PLASTIDS
WO2006081139A2 (en)	2005-01-26	2006-08-03	Abgenix, Inc.	Antibodies against interleukin-1 beta
KR101289537B1 (ko)	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
AU2006216291B2 (en)	2005-02-27	2011-01-27	Institute For Antibodies Co., Ltd.	Anti-IgSF4 antibody and utilization of the same
ATE549358T1 (de)	2005-03-24	2012-03-15	Thrombogenics Nv	Neuer anti-plgf-antikörper
CN101484182B (zh)	2005-04-06	2014-06-11	Ibc药品公司	由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
AP2007004243A0 (en)	2005-04-25	2007-12-31	Pfizer	Antibodies to myostatin
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
EP1885755A4 (en)	2005-05-05	2009-07-29	Univ Duke	CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
JP5339901B2 (ja)	2005-05-10	2013-11-13	バイオジェン・アイデック・エムエイ・インコーポレイテッド	炎症傷害の処置および評価
WO2006130429A2 (en)	2005-05-27	2006-12-07	Biogen Idec Ma Inc.	Treatment of cancer
UA96416C2 (uk)	2005-05-27	2011-11-10	Байоджэн Айдэк Ма Инк.	Антитіло, яке зв'язується з tweak людини
ITRM20050290A1 (it)	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
KR20080017025A (ko)	2005-06-24	2008-02-25	노보자임스 에이/에스	약학적 용도의 리파제
PT1896073E (pt)	2005-06-30	2013-05-28	Janssen Biotech Inc	Composições, métodos e aplicações de anticorpos anti-il-23
ATE483802T1 (de)	2005-08-11	2010-10-15	Synthetic Genomics Inc	Verfahren zur in vitro-rekombination
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
AU2006283532B2 (en) *	2005-08-19	2012-04-26	Abbvie Inc.	Dual variable domain immunoglobin and uses thereof
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
NO345919B1 (no)	2005-08-26	2021-10-18	Roche Glycart Ag	Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
US7906116B2 (en)	2005-09-01	2011-03-15	Parkash Gill	Methods for using and identifying modulators of Delta-like 4
CA2862540C (en)	2005-09-21	2018-07-31	The Regents Of The University Of California	Systems, compositions, and methods for local imaging and treatment of pain
US9119828B2 (en)	2005-09-23	2015-09-01	The United States Of America As Represented By The Secretary Of The Army	Antibodies with simultaneous subsite specificities to protein and lipid epitopes
EP3770174A1 (en)	2005-10-11	2021-01-27	Amgen Research (Munich) GmbH	Compositions comprising cross-species-specific antibodies and uses thereof
US20080299137A1 (en)	2005-10-28	2008-12-04	Novo Nordisk A/S	Fusion Proteins That Bind Effector Lymphocytes And Target Cells
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
TW200736277A (en)	2005-11-14	2007-10-01	Amgen Inc	RANKL antibody-PTH/PTHrP chimeric molecules
AP2809A (en)	2005-11-18	2013-12-31	Glenmark Pharmaceuticals Sa	Anti-Alpha2 Integrin antibodies and their uses
US7820165B2 (en)	2005-11-21	2010-10-26	Merck Serono, S.A.	Compositions and methods of producing hybrid antigen binding molecules and uses thereof
CA2628703C (en)	2005-11-30	2019-10-29	Abbott Laboratories	Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1979001T3 (da)	2005-12-13	2012-07-16	Medimmune Ltd	Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
AR056857A1 (es)	2005-12-30	2007-10-24	U3 Pharma Ag	Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US8688495B2 (en)	2005-12-30	2014-04-01	Sap Ag	Architectural design for time recording application software
KR101535678B1 (ko)	2006-01-23	2015-07-09	조셉 피. 에리코	표적 약물 개발의 방법 및 조성물
US8377691B2 (en)	2006-01-26	2013-02-19	Integral Molecular, Inc.	Lipoparticles comprising ion channels, methods of making and using the same
WO2007117749A2 (en) *	2006-01-31	2007-10-18	Novartis Ag	Il-17 antagonistic antibodies fpr treating cancer
US20070207171A1 (en)	2006-03-01	2007-09-06	Cerus Corporation	Engineered listeria and methods of use thereof
SG170750A1 (en)	2006-03-17	2011-05-30	Biogen Idec Inc	Stabilized polypeptide compositions
MX2008012023A (es)	2006-03-21	2008-10-01	Wyeth Corp	Metodos para prevenir y tratar enfermedades amiloidogenicas.
ES2395969T3 (es)	2006-03-24	2013-02-18	Merck Patent Gmbh	Dominios de proteínas heterodiméricas genéticamente modificados
BRPI0709843A2 (pt)	2006-03-28	2011-07-26	Biogen Idec Inc	anticorpos de anti-igf-1r e usos dos mesmos
US20070232556A1 (en)	2006-03-31	2007-10-04	Montine Thomas J	Methods and compositions for the treatment of neurological diseases and disorders
WO2007120651A2 (en)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of juvenile rheumatoid arthritis
BRPI0709977A2 (pt)	2006-04-14	2011-08-02	Novartis Ag	uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
US8173860B2 (en)	2006-04-21	2012-05-08	Gtc Biotherapeutics, Inc.	Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
BRPI0710826A2 (pt)	2006-04-21	2011-08-23	Novartis Ag	composições farmacêuticas de anticorpo anti-cd40 antagonista
US20070254338A1 (en)	2006-04-24	2007-11-01	Amgen Inc.	Method for making recombinant protein using complementation dependent DHFR mutants
US20080118978A1 (en)	2006-04-28	2008-05-22	Takashi Sato	Anti-tumor agent
CN101058609B (zh)	2006-05-26	2011-04-13	神州细胞工程有限公司	人源抗体及其表达
NZ573819A (en)	2006-06-02	2011-09-30	Aveo Pharmaceuticals Inc	Hepatocyte growth factor (hgf) binding proteins
CA2654304A1 (en)	2006-06-06	2007-12-13	Genentech, Inc.	Compositions and methods for modulating vascular development
CL2007001623A1 (es)	2006-06-06	2008-01-18	Genentech Inc	Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
CN1884517B (zh)	2006-06-08	2010-06-30	武汉禾元生物科技有限公司	利用谷物非储藏蛋白为融合载体在胚乳表达多肽的方法及应用
WO2007147901A1 (en)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production of bispecific antibodies
ES2427924T3 (es)	2006-06-30	2013-11-04	Merck Sharp & Dohme Corp.	Biomarcador IGFBP2
US20080081379A1 (en)	2006-07-13	2008-04-03	Sigler Gerald F	Homogeneous double receptor agglutination assay for immunosuppressant drugs
PL2468770T3 (pl)	2006-07-14	2018-07-31	Ac Immune S.A.	Humanizowane przeciwciało przeciw amyloidowi beta
US7592156B2 (en)	2006-07-20	2009-09-22	Wyeth	Synthetic dog/human chimeric C-C chemokine receptor 2B
CA2660171C (en)	2006-08-11	2017-05-16	Monsanto Technology Llc	Production of high tryptophan maize by chloroplast targeted expression of anthranilate synthase
HRP20140331T1 (hr)	2006-08-14	2014-05-09	Xencor, Inc.	Optimizirana antitijela usmjerena na cd19
KR101625961B1 (ko)	2006-09-08	2016-05-31	애브비 바하마스 리미티드	인터루킨-13 결합 단백질
US20080075690A1 (en)	2006-09-22	2008-03-27	Mark Douglas Howell	Method for enhancing immune responses in mammals
SI2066694T1 (sl)	2006-09-29	2016-02-29	Oncomed Pharmaceuticals, Inc.	Sestavki in postopki za diagnosticiranje in zdravljenje raka
US20080102475A1 (en)	2006-10-13	2008-05-01	Zhengyan Kan	Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
EP2684895A1 (en)	2006-10-27	2014-01-15	AbbVie Biotechnology Ltd	Crystalline anti-hTNFalpha antibodies
AU2007313685C1 (en) *	2006-11-02	2015-09-17	Genentech, Inc.	Humanized anti-Factor D antibodies
AU2007338734A1 (en)	2006-12-20	2008-07-03	Vasgene Therapeutics, Inc.	Methods for using and identifying modulators of delta-like 4
DE602008004296D1 (de) *	2007-02-14	2011-02-17	Vaccinex Inc	Humanisierte anti-cd100-antikörper
SI2716301T1 (sl)	2007-02-16	2017-07-31	Merrimack Pharmaceuticals, Inc.	Protitelesa proti ErbB3 in uporaba le-teh
MY166021A (en)	2007-03-22	2018-05-21	Biogen Ma Inc	Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof
US7906293B2 (en)	2007-04-09	2011-03-15	Abbott Laboratories	Acridinium phenyl esters useful in the analysis of biological
RU2009140134A (ru)	2007-04-23	2011-05-27	Вайет (Us)	Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
GB0708002D0 (en)	2007-04-25	2007-06-06	Univ Sheffield	Antibodies
EP1997832A1 (en)	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
DK2164992T3 (en)	2007-05-30	2016-08-15	Lpath Inc	COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
WO2009003142A1 (en)	2007-06-27	2008-12-31	The Board Of Trustees Of The Leland, Stanford Junior University	Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
EP2626371A1 (en)	2007-07-31	2013-08-14	MedImmune, LLC	Multispecific epitope binding proteins and uses thereof
WO2009020654A1 (en)	2007-08-08	2009-02-12	Abbott Laboratories	Compositions and methods for crystallizing antibodies
CA2696263C (en)	2007-08-15	2017-06-13	Bing Liu	Monospecific and multispecific antibodies and method of use
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
JP5746861B2 (ja)	2007-10-19	2015-07-08	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	哺乳動物のｎｇａｌに結合する抗体及びその使用
JP5737944B2 (ja)	2007-12-17	2015-06-17	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	間質性膀胱炎の治療
AU2009204501B2 (en)	2008-01-07	2015-02-12	Amgen Inc.	Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2009091912A2 (en)	2008-01-15	2009-07-23	Abbott Laboratories	Improved mammalian expression vectors and uses thereof
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
JP5470817B2 (ja)	2008-03-10	2014-04-16	日産自動車株式会社	電池用電極およびこれを用いた電池、並びにその製造方法
EP2899209A1 (en)	2008-04-29	2015-07-29	Abbvie Inc.	Dual Variable Domain Immunoglobulins and uses thereof
US20100260668A1 (en)	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
CA2723219A1 (en)	2008-05-09	2009-11-12	Abbott Gmbh & Co. Kg	Antibodies to receptor of advanced glycation end products (rage) and uses thereof
BRPI0913406A2 (pt)	2008-06-03	2018-01-09	Abbott Lab	imunoglobulinas de domínio variável duplo e usos das mesmas
EP2297208A4 (en)	2008-06-03	2012-07-11	Abbott Lab	DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US8741287B2 (en)	2008-06-18	2014-06-03	Abbott Laboratories	PlGF-1 assay and kits and components thereof
BRPI0915825A2 (pt)	2008-07-08	2015-11-03	Abbott Lab	proteínas de ligação à prostaglandina e2 usos das mesmas
US8822645B2 (en)	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
WO2010017103A2 (en)	2008-08-04	2010-02-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic	Fully human anti-human nkg2d monoclonal antibodies
CA2737035A1 (en)	2008-09-30	2010-04-08	Abbott Laboratories	Improved method of rna display
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010065882A1 (en)	2008-12-04	2010-06-10	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
TW201613969A (en)	2009-03-05	2016-04-16	Abbvie Inc	IL-17 binding proteins
JP2012525155A (ja)	2009-05-01	2012-10-22	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリンおよびこの使用
MX2011011670A (es)	2009-05-01	2011-11-18	Abbott Lab	Inmunoglobulinas de dominio variable dual y usos de las mismas.
TW201109438A (en)	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CA2771575A1 (en)	2009-08-29	2011-03-03	Abbott Laboratories	Therapeutic dll4 binding proteins
RU2012112550A (ru)	2009-09-01	2013-10-10	Эбботт Лэборетриз	Иммуноглобулины с двумя вариабельными доменами и их применение
UY32920A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US8716450B2 (en)	2009-10-15	2014-05-06	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
UY32949A (es) *	2009-10-15	2011-02-28	Abbott Lab	Proteínas de unión a il-1
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011084714A2 (en)	2009-12-17	2011-07-14	Biogen Idec Ma Inc.	STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
WO2011091304A1 (en)	2010-01-22	2011-07-28	Genentech, Inc.	Delivery system for diagnostic and therapeutic agents
CA2791631A1 (en)	2010-03-02	2011-09-09	Abbvie Inc.	Therapeutic dll4 binding proteins
US8841417B2 (en) *	2010-05-14	2014-09-23	Abbvie Inc.	IL-1 binding proteins
SG188944A1 (en)	2010-06-24	2013-05-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201206473A (en)	2010-08-03	2012-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es)	2010-08-26	2014-03-27	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2014500712A (ja)	2010-11-02	2014-01-16	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリンおよびその使用
AR083705A1 (es)	2010-11-04	2013-03-13	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112013013083A2 (pt)	2010-11-30	2016-12-13	Genentech Inc	métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
KR20130133247A (ko)	2010-12-21	2013-12-06	애브비 인코포레이티드	Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012088302A2 (en)	2010-12-22	2012-06-28	Abbott Laboratories	Half immunoglobulin binding proteins and uses thereof
MX341578B (es)	2011-02-08	2016-08-25	Abbvie Inc	Tratamiento de la osteoartritis y del dolor.
BR112013026423A2 (pt)	2011-04-20	2016-11-29	Roche Glycart Ag	método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
PT3485903T (pt)	2011-09-23	2023-02-17	Mereo Biopharma 5 Inc	Agentes de ligação a vegf/dll4 e utilizações dos mesmos
CN104203978A (zh)	2011-10-24	2014-12-10	艾伯维股份有限公司	针对硬化蛋白的免疫结合剂
IN2014CN03936A (es)	2011-10-24	2015-09-04	Abbvie Inc
HK1200321A1 (en)	2011-10-24	2015-08-07	Abbvie Inc.	Bispecific immunobinders directed against tnf and il-17
HK1202444A1 (en)	2011-11-21	2015-10-02	Abbvie Inc.	Il-1 binding proteins
TW201333033A (zh)	2011-12-30	2013-08-16	Abbvie Inc	雙可變域免疫球蛋白及其用途
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
BR112014016299A8 (pt)	2011-12-30	2017-07-04	Abbvie Inc	imunoglobulinas de domínio variável e usos das mesmas
EP2807192B1 (en)	2012-01-27	2018-04-18	Abbvie Deutschland GmbH & Co. KG	Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
KR102031317B1 (ko)	2012-05-21	2019-10-14	제넨테크, 인크.	혈액-뇌 장벽 수송의 안전성을 개선하는 방법
UY35110A (es)	2012-11-01	2014-05-30	Abbvie Inc	Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
SG11201503324WA (en)	2012-11-01	2015-05-28	Abbvie Inc	Stable dual variable domain immunoglobulin protein formulations
BR112015012014A2 (pt)	2012-12-04	2017-07-11	Abbvie Inc	proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
WO2014106001A2 (en)	2012-12-28	2014-07-03	Abbvie, Inc.	Dual specific binding proteins having a receptor sequence
US20140213772A1 (en)	2012-12-28	2014-07-31	Abbvie, Inc.	Cross-over dual variable domain immunoglobulin constructs
US20140213771A1 (en)	2012-12-28	2014-07-31	Abbvie, Inc.	Multi-specific binding proteins
US9458244B2 (en)	2012-12-28	2016-10-04	Abbvie Inc.	Single chain multivalent binding protein compositions and methods
EP2938637A2 (en)	2012-12-28	2015-11-04	AbbVie Inc.	Multivalent binding protein compositions
US9856319B2 (en)	2012-12-28	2018-01-02	Abbvie Inc.	Monovalent binding proteins
US20140235476A1 (en)	2012-12-28	2014-08-21	Abbvie, Inc.	Multivalent binding protein compositions and methods for identifying variants of same
JP6136279B2 (ja)	2013-01-15	2017-05-31	株式会社ジェイテクト	転がり軸受装置
CA2904448A1 (en)	2013-03-15	2014-09-18	Tariq Ghayur	Dual specific binding proteins directed against il-1.beta. and/or il-17
TW201446800A (zh)	2013-03-15	2014-12-16	Abbvie Inc	針對ＴＮＦα之雙特異性結合蛋白
TWI503850B (zh)	2013-03-22	2015-10-11	Polytronics Technology Corp	過電流保護元件
JP2016527260A (ja)	2013-08-02	2016-09-08	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	治療用融合タンパク質
TWI510996B (zh)	2013-10-03	2015-12-01	Acer Inc	控制觸控面板的方法以及使用該方法的可攜式電腦
WO2015138337A1 (en)	2014-03-09	2015-09-17	Abbvie, Inc.	Compositions and methods for treating rheumatoid arthritis
US20160002343A1 (en)	2014-06-11	2016-01-07	Abbvie Inc.	Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
US9816280B1 (en)	2016-11-02	2017-11-14	Matthew Reitnauer	Portable floor

2011
- 2011-08-02 TW TW100127463A patent/TW201206473A/zh unknown
- 2011-08-02 US US13/196,138 patent/US8735546B2/en active Active
- 2011-08-02 EP EP11815172.9A patent/EP2601218A4/en not_active Withdrawn
- 2011-08-02 AR ARP110102792A patent/AR082461A1/es unknown
- 2011-08-02 CN CN2011800481595A patent/CN103298834A/zh active Pending
- 2011-08-02 PH PH1/2013/500207A patent/PH12013500207A1/en unknown
- 2011-08-02 KR KR1020137005479A patent/KR20130100118A/ko not_active Withdrawn
- 2011-08-02 AU AU2011285852A patent/AU2011285852B2/en not_active Ceased
- 2011-08-02 NZ NZ607480A patent/NZ607480A/en not_active IP Right Cessation
- 2011-08-02 WO PCT/US2011/046233 patent/WO2012018790A2/en not_active Ceased
- 2011-08-02 UY UY0001033543A patent/UY33543A/es not_active Application Discontinuation
- 2011-08-02 RU RU2013109275/10A patent/RU2013109275A/ru not_active Application Discontinuation
- 2011-08-02 SG SG2013008040A patent/SG188190A1/en unknown
- 2011-08-02 BR BR112013002578-6A patent/BR112013002578A2/pt active Search and Examination
- 2011-08-02 JP JP2013523268A patent/JP2013537415A/ja active Pending
- 2011-08-02 CA CA2807014A patent/CA2807014A1/en not_active Abandoned
- 2011-08-02 PE PE2013000182A patent/PE20131412A1/es not_active Application Discontinuation
- 2011-08-02 MY MYPI2013700180A patent/MY160445A/en unknown
- 2011-08-02 MX MX2013001362A patent/MX341579B/es active IP Right Grant
- 2011-08-02 EP EP17167833.7A patent/EP3252072A3/en not_active Withdrawn
2013
- 2013-01-31 DO DO2013000025A patent/DOP2013000025A/es unknown
- 2013-02-01 CL CL2013000338A patent/CL2013000338A1/es unknown
- 2013-02-08 CR CR20130058A patent/CR20130058A/es unknown
- 2013-02-27 EC ECSP13012462 patent/ECSP13012462A/es unknown
- 2013-02-28 CO CO13041045A patent/CO6680687A2/es unknown
- 2013-12-19 US US14/135,107 patent/US9493560B2/en active Active
- 2013-12-19 US US14/135,126 patent/US20140219912A1/en not_active Abandoned
- 2013-12-19 US US14/135,149 patent/US20140220019A1/en not_active Abandoned
2016
- 2016-06-13 JP JP2016116860A patent/JP2016198102A/ja active Pending
- 2016-09-20 US US15/270,945 patent/US20170226200A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2013537415A (ja)	2013-10-03
US20170226200A1 (en)	2017-08-10
BR112013002578A2 (pt)	2019-05-14
MX341579B (es)	2016-08-25
NZ607480A (en)	2014-10-31
CR20130058A (es)	2013-06-12
CN103298834A (zh)	2013-09-11
US20120034160A1 (en)	2012-02-09
WO2012018790A2 (en)	2012-02-09
US8735546B2 (en)	2014-05-27
WO2012018790A4 (en)	2012-07-12
US20140234208A1 (en)	2014-08-21
WO2012018790A3 (en)	2012-05-31
AU2011285852A1 (en)	2013-03-14
EP2601218A2 (en)	2013-06-12
US20140220019A1 (en)	2014-08-07
JP2016198102A (ja)	2016-12-01
US9493560B2 (en)	2016-11-15
MX2013001362A (es)	2013-07-17
US20140219912A1 (en)	2014-08-07
EP2601218A4 (en)	2015-02-18
AR082461A1 (es)	2012-12-12
DOP2013000025A (es)	2014-01-31
RU2013109275A (ru)	2014-09-10
EP3252072A2 (en)	2017-12-06
UY33543A (es)	2012-02-29
CA2807014A1 (en)	2012-02-09
MY160445A (en)	2017-03-15
EP3252072A3 (en)	2018-03-14
ECSP13012462A (es)	2013-03-28
SG188190A1 (en)	2013-04-30
PH12013500207A1 (en)	2017-08-23
TW201206473A (en)	2012-02-16
PE20131412A1 (es)	2014-01-19
KR20130100118A (ko)	2013-09-09
CO6680687A2 (es)	2013-05-31
AU2011285852B2 (en)	2014-12-11

Publication	Publication Date	Title
CL2013000338A1 (es)	2013-11-08	Proteina de union que tiene la capacidad de unirse a interleuquina 1beta y a la interleuquina 17; conjugado de proteina de union cristalizada; acido nucleico, vector, célula huesped; metodo para producir una proteina de unión; composicion farmacéutica que comprende la proteina de unión.
CL2013000543A1 (es)	2013-11-08	Proteina de union que tiene la capacidad de unirse al factor de necrosis tumoral (tnf) y el factor de crecimiento nervioso (ngf); conjugado de proteina de union cristalizada; acido nucleico, vector, célula huesped; metodo para producir una proteina de unión; composicion farmacéutica que comprende la proteina de unión.
IL262073B (en)	2020-11-30	Antibody drug conjugates (adc) that bind to 191p4d12 proteins
CL2013000074A1 (es)	2013-12-06	Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CY1122978T1 (el)	2021-10-29	Αντισωματα εναντι-vla-4
CL2012002416A1 (es)	2013-09-06	Proteina de union capaz de unirse a dll4; construccion de anticuerpo que comprende dicha proteina; conjugado de anticuerpo; acido nucleico, vector y celula huesped que comprenden el anticuerpo; composicion para la liberacion de una proteina de union; metodo para reducir la actividad del dll4 humano.
BR112013029893A2 (pt)	2017-05-30	molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
LT2563400T (lt)	2019-10-10	Modifikuoti surišantys baltymai, slopinantys vegf-a receptoriaus sąveiką
IL252154A0 (en)	2017-07-31	Anti-dr5 antibodies, compositions comprising the same and uses thereof
CL2014001254A1 (es)	2014-10-10	Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
BR112014000263A2 (pt)	2017-02-14	anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
CL2016002340A1 (es)	2017-06-02	Proteínas de unión al antígeno cd27l; ácido nucleico que la codifica; vector de expresión; célula huésped recombinante; composición que la comprende; su uso para tratar cáncer, trastornos autoinmunitarios o inflamatorios; y método para elaborar un conjugado anticuerpo cd27l-fármaco (divisional sol. n° 699-14).
HK1216894A1 (zh)	2016-12-09	多價結合蛋白組合物
HUE037651T2 (hu)	2018-09-28	B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák
SI3590949T1 (sl)	2022-09-30	Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
BR112014028785A2 (pt)	2017-07-18	proteínas de ligação a antígeno de st2
IL221205A0 (en)	2012-10-31	Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
BRPI0919388A2 (pt)	2018-03-13	ácido succínico e método para produzir o mesmo.
BR112013007229A2 (pt)	2016-06-14	''composição,mistura e processo''.
GB0922209D0 (en)	2010-02-03	Proteins, nucleic acid molecules and compositions
IL210485A (en)	2015-03-31	An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
FR2941231B1 (fr)	2016-04-01	Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
PT2427212T (pt)	2017-11-20	Anticorpos anti-cd100 e métodos para utilização dos mesmos
DK2723771T3 (da)	2019-12-02	Serumalbuminbindende proteiner
BR112012032357A2 (pt)	2015-11-24	método, sistema para produção de produto fermentativo e composição